Unmasking PD-1 Resistance by Next-Generation Sequencing

Abstract excerpt

Monoclonal antibodies that inhibit the programmed death 1 (PD-1)–programmed death ligand 1 (PD-L1) pathway are clinically active against a broad range of tumors; however, even the most susceptible tumors (e.g., melanoma) respond less than half the time because of innate resistance. In this issue of the Journal, Zaretsky et al.1 describe the use of whole-exome sequencing to identify mechanisms of acquired immune...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Immunotherapy and Biomarkers
• Share to CAR-T cell therapy research
• Share to Immunotherapy and Immune Responses